EHD2 and breast cancer: Significantly, EHD2 and CAV1 or CAV2 mRNA overexpression predicted shorter patient survival specifically in the PAM50-defined basal BC (Figure 7B), consistent with the predominant basal (myoepithelial) cell expression of EHD2 in mouse mammary epithelium (Figure 1B and D).